Results 21 to 30 of about 5,352 (210)

Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development

EBioMedicine, 2022
Summary: Background: SJ733, a newly developed inhibitor of P. falciparum ATP4, has a favorable safety profile and rapid antiparasitic effect but insufficient duration to deliver a single-dose cure of malaria.
Aditya H. Gaur, John C. Panetta, Amber M. Smith, Ronald H. Dallas, Burgess B. Freeman, III, Tracy B. Stewart, Li Tang, Elizabeth John, Kristen C. Branum, Nehali D. Patel, Shelley Ost, Ryan N. Heine, Julie L. Richardson, Jared T. Hammill, Lidiya Bebrevska, Fabian Gusovsky, Noritsugu Maki, Toshiharu Yanagi, Patricia M. Flynn, James S. McCarthy, Stephan Chalon, R. Kiplin Guy   +21 more
doaj   +1 more source

Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV [PDF]

, 2021
OBJECTIVE: To evaluate darunavir and cobicistat pharmacokinetics during pregnancy compared to postpartum and in infant washout samples after delivery. DESIGN: Nonrandomized, open-label, parallel-group, multi-center phase-IV prospective study of darunavir
RUNGRUENGTHANAKIT, Kittipong, Mark Mirochnick, Kayla Denson, Mary E. Paul, Sandra Burchett, MOMPER, Jeremiah D., Best, Brookie M, Alice Stek, SHAPIRO, David E., David E. Shapiro, BEST, Brookie M., Jeremiah D. Momper, BURCHETT, Sandra, YANG, Derek, Yang, Derek Z, CAPPARELLI, Edmund V., WANG, Jiajia, Kathleen George, STEK, Alice, Capparelli, Edmund V, CHAKHTOURA, Nahida, DENSON, Kayla, Momper, Jeremiah D, Shapiro, David E, FEBO, Irma L., PAUL, Mary E., SMITH, Elizabeth, Jiajia Wang, Kittipong Rungruengthanakit, Nahida Chakhtoura, Gwendolyn B. Scott, Irma L. Febo, Brookie M. Best, Elizabeth Smith, Febo, Irma L, Derek Z. Yang, GEORGE, Kathleen, Edmund V. Capparelli, SCOTT, Gwendolyn B., Scott, Gwendolyn B, Paul, Mary E, MIROCHNICK, Mark   +41 more
core   +1 more source

Protocol of the IntenSify‐Trial: An open‐label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy

Clinical and Translational Science, 2023
Expression of CYP3A5 protein is a basal and acquired resistance mechanism of pancreatic ductal adenocarcinoma cells conferring protection against the CYP3A and CYP2C8 substrate paclitaxel through metabolic degradation.
Nicolas Hohmann, Martin Ronald Sprick, Moritz Pohl, Azaz Ahmed, Jürgen Burhenne, Marietta Kirchner, Lucian Le Cornet, Markus Kratzmann, Jacek Hajda, Albrecht Stenzinger, Karen Steindorf, Stefan Delorme, Heinz‐Peter Schlemmer, Sabine Riethdorf, Ron vanSchaik, Klaus Pantel, Jens Siveke, Thomas Seufferlein, Dirk Jäger, Walter E. Haefeli, Andreas Trumpp, Christoph Springfeld   +21 more
doaj   +1 more source

The screening and evaluation of potential clinically significant HIV drug combinations against the SARS-CoV-2 virus

Informatics in Medicine Unlocked, 2021
Spike glycoprotein is essential for the reproduction of the SARS-CoV-2 virus, and its inhibition using already approved antiviral drugs may open new avenues for treatment of patients with the COVID-19 disease.
Draško Tomić, Davor Davidović, Attila Marcel Szasz, Melinda Rezeli, Boris Pirkić, Jozsef Petrik, Vesna Bačić Vrca, Vladimir Janđel, Tomislav Lipić, Karolj Skala, Josip Mesarić, Marija Milković Periša, Zorislav Šojat, Branka Medved Rogina   +13 more
doaj   +1 more source

Pharmacological aspects of darunavir/cobicistat [PDF]

, 2016
Rezolsta® (darunavir/cobicistat) es el primer inhibidor de la proteasa potenciado en combinación fija con un nuevo potenciador farmacológico. Darunavir es actualmente el inhibidor de la proteasa de uso preferente con un perfil de eficacia y seguridad ...
Santos-González, Jesús Leandro, González-Doménech, Carmen María, Palacios-Muñoz, María Rosario   +2 more
core   +1 more source

A rare complication of coronary vasospasm associated with concomitant use of ergotamine, cobicistat, and darunavir

Antiviral Therapy, 2022
Ergotism is a rare cause of peripheral vasoconstriction with varying presentation depending on the affected vessels. Coronary vasospasm is a rare, potentially fatal manifestation of ergotism.
Cheng-En Wu, Chun-Hsien Wu, Shih-Hung Tsai, Wen-I Liao   +3 more
doaj   +1 more source

Advances in New Approach Methodologies at FDA's Division of Applied Regulatory Science. [PDF]

Clin Pharmacol Ther
New Approach Methodologies (NAMs) represent a paradigm shift in drug development and regulatory science, offering human‐relevant alternatives to traditional preclinical models. This mini‐review highlights recent advances in NAM development, validation, and regulatory application from FDA's Division of Applied Regulatory Science (DARS).
Blinova K, Chiu K, Chaturbedi A, Cooper J, Feaster TK, Hyland PL, Stavitskaya L, Wu WW, Florian J, Rouse R.   +9 more
europepmc   +2 more sources

Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting

Antiviral Therapy, 2023
Background Cohort studies suggest higher discontinuation rates with integrase strand transfer inhibitors (INSTIs) than are seen in clinical trials. We assessed discontinuations and adverse events (AEs) that were considered related to the initial INSTI in
Charlotte-Paige Rolle MD, MPH, Jamie Castano, Vu Nguyen MS, Kiran Patel, Federico Hinestrosa MD, Edwin DeJesus MD   +5 more
doaj   +1 more source

Pharmacokinetics of Atazanavir Boosted With Cobicistat in Pregnant and Postpartum Women With HIV [PDF]

, 2022
BACKGROUND: This study evaluated atazanavir and cobicistat pharmacokinetics during pregnancy compared with postpartum and in infant washout samples. SETTING: A nonrandomized, open-label, parallel-group, multicenter prospective study of atazanavir and ...
Mark Mirochnick, George, Kathleen, Kayla Denson, Mary E. Paul, Kathleen M. Powis, Martina L. Badell, Best, Brookie M, Alice Stek, David E. Shapiro, Denson, Kayla, Jeremiah D. Momper, Kathleen George, Capparelli, Edmund V, Stek, Alice, Mirochnick, Mark, Powis, Kathleen M, Momper, Jeremiah D, Shapiro, David E, Renee Browning, Wang, Jiajia, Jiajia Wang, Browning, Renee, Kittipong Rungruengthanakit, Nahida Chakhtoura, Badell, Martina L, Brookie M. Best, Edmund V. Capparelli, Rungruengthanakit, Kittipong, Chakhtoura, Nahida, Paul, Mary E, Team, for the IMPAACT P1026s Protocol   +30 more
core   +1 more source

Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences

, 2017
Objective: To describe properties of cobicistat and ritonavir; compare boosting data with atazanavir, darunavir, and elvitegravir; and summarize antiretroviral and comedication interaction studies, with a focus on similarities and differences between ...
Jason Seet, Janet Wu, Alice Tseng, Elizabeth J. Phillips, Christine A. Hughes   +4 more
core   +2 more sources